https://www.onhealthcare.tech/p/cms-0062-p-deep-dive-what-the-2026Thoughts on Healthcare Markets and Technologyen2026-04-16T13:19:04+00:00CMS-0062-P Deep Dive: What the 2026 Interoperability and Prior Authorization for Drugs Proposed Rule Actually Means for Health Tech Investors and Entrepreneurshttps://www.onhealthcare.tech/p/the-fda-just-rewrote-the-rules-forThoughts on Healthcare Markets and Technologyen2026-04-15T23:59:04+00:00The FDA Just Rewrote the Rules for Gene Therapy Approval & Most Investors Haven’t Noticed Yet: The Plausible Mechanism Framework and NGS Safety Guidance That Could Reshape Rare Disease Investmenthttps://www.onhealthcare.tech/p/a-blunt-assessment-of-every-majorThoughts on Healthcare Markets and Technologyen2026-04-15T11:56:22+00:00A Blunt Assessment of Every Major ACCESS Model Participant, Their Business Models, and What CMS’s New Outcome-Aligned Payment Framework Actually Means for Their P&L and Patient Populations